Point of Care Diagnostics Market - Global Forecast 2026-2032

List of Tables

The Point of Care Diagnostics Market is projected to grow by USD 83.86 billion at a CAGR of 8.10% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 48.59 billion
Estimated Year [2026]	USD 52.39 billion
Forecast Year [2032]	USD 83.86 billion
CAGR (%)	8.10%

Point-of-Care Diagnostics: Executive Summary

Point-of-care diagnostics (POCD) encompass tests performed near or at the patient rather than exclusively in centralized laboratories. The field includes rapid infectious-disease testing, blood-glucose monitoring, pregnancy testing, cardiac and critical-care assays, molecular platforms, and other decentralized diagnostic applications. Its strategic importance is linked to faster clinical decisions, improved access, and the growing need to extend diagnostic capacity beyond hospitals and reference laboratories.

Decentralization, Connectivity, and Workflow Integration Are Reshaping POCD

The landscape is shifting from standalone rapid tests toward connected diagnostic workflows that combine portable instruments, disposable assays, digital records, remote oversight, and clinical decision support. Demand is being influenced by hospital overcrowding, decentralized care, chronic-disease management, emergency response, and the need for testing in pharmacies, clinics, ambulances, workplaces, and community settings. Regulatory scrutiny, quality assurance, operator training, reimbursement alignment, and interoperability remain essential to converting technical capability into dependable clinical value.

Artificial Intelligence Is Strengthening Interpretation, Triage, and Quality Control

Artificial intelligence is being applied to interpret complex signals, prioritize abnormal results, support image-based diagnostics, identify testing errors, and assist clinicians in triage. Its greatest near-term contribution is likely to come from augmenting trained users rather than replacing them, particularly where results require contextual interpretation or integration with patient histories. Successful deployment depends on representative validation data, transparent performance monitoring, cybersecurity, privacy safeguards, human oversight, and clear accountability when algorithmic recommendations influence care.

Regional Insights: Access Priorities Differ Across Six Broad Geographies

North America emphasizes connected care, regulatory compliance, hospital efficiency, and chronic-disease monitoring. Europe combines strong laboratory standards with interest in decentralized services, cross-border data governance, and integrated health systems. Asia-Pacific spans advanced digital-health ecosystems and substantial access gaps, creating demand for portable, robust, and easy-to-use platforms. Latin America prioritizes affordability, decentralized screening, and continuity of care across uneven infrastructure. The Middle East is investing in modern healthcare networks, emergency readiness, and technology-enabled services, while Africa places particular emphasis on rugged platforms, supply-chain resilience, community-based delivery, and workforce enablement.

Group Insights: Policy and Economic Blocs Shape Adoption Conditions

ASEAN countries share priorities around infectious-disease preparedness, distributed care, and solutions suited to varied health-system capacity. BRICS members reflect diverse approaches to domestic manufacturing, affordability, public-sector procurement, and broad population access. The European Union places weight on safety, evidence, interoperability, and data governance across member states. G7 markets generally emphasize advanced clinical integration, cybersecurity, validation, and efficiency in mature health systems. GCC countries are pursuing digitally enabled healthcare modernization and centralized procurement capabilities. NATO members also have an interest in resilient medical logistics, emergency preparedness, and interoperable response systems, although adoption conditions vary by national health policy.

Country Insights: National Health Priorities Define POCD Opportunities

Australia is suited to decentralized testing because of geographic dispersion and remote-care requirements. Brazil and Mexico face opportunities in primary care, infectious-disease screening, and access across regional health disparities. Canada's geography supports remote diagnostics and connected services. China is advancing domestic capability, hospital digitization, and broad healthcare access, while India emphasizes affordability, scale, primary care, and community deployment. Japan and South Korea combine sophisticated healthcare infrastructure with strong interest in automation and aging-related care. France, Germany, Italy, Spain, and the United Kingdom are shaped by public-health systems, evidence requirements, workforce pressures, and care integration. Russia's environment is influenced by domestic supply considerations and geographically distributed service needs. The United States emphasizes decentralized testing, clinical workflow integration, regulatory evidence, and home-based monitoring.

Actions for Leaders: Build Trustworthy, Interoperable, and Deployable Solutions

Industry leaders should prioritize clearly defined clinical use cases and design products around real workflows rather than laboratory performance alone. Evidence plans should address analytical validity, clinical utility, usability, operator variability, and performance across relevant populations. Interoperability with electronic health records, secure connectivity, remote quality control, and transparent reporting can improve adoption. Organizations should also strengthen supply-chain resilience, provide structured training, support maintenance in low-resource settings, and align commercial models with reimbursement and public procurement. AI-enabled products require continuous monitoring, bias assessment, explainability appropriate to the use case, and explicit human escalation pathways.

Research Methodology: Evidence-Led Assessment of a Diverse Diagnostic Field

This executive summary uses a structured assessment of point-of-care diagnostics across technologies, clinical applications, care settings, stakeholders, and geographies. The approach distinguishes verified operational, clinical, regulatory, and adoption trends from unsupported claims. Regional, group, and country perspectives are synthesized from established healthcare-system characteristics, public policy priorities, diagnostic-access conditions, and technology adoption patterns. Interpretations are framed qualitatively, with no market estimates, sizing, shares, or forecasts, and should be complemented by current regulatory documents, peer-reviewed evidence, procurement records, and local clinical guidance when used for decisions.

Conclusion: POCD Value Depends on Clinical Reliability and System Fit

Point-of-care diagnostics are becoming an important component of distributed healthcare, but their impact depends on more than speed or portability. Reliable results, appropriate clinical governance, connected workflows, equitable access, and sustainable support determine whether decentralized testing improves care. Leaders that combine validated technology with strong implementation, data stewardship, workforce enablement, and regional responsiveness will be better positioned to deliver dependable diagnostic value across hospitals, communities, and homes.

Product Code: MRR-7036D9112993

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Point of Care Diagnostics Market, by Product

7.1. Introduction
7.2. Consumables
- 7.2.1. Assay Kits
- 7.2.2. Reagents
- 7.2.3. Test Strips
7.3. Instruments
- 7.3.1. Benchtop Analyzers
- 7.3.2. Handheld Analyzers
- 7.3.3. Portable Readers

8. Point of Care Diagnostics Market, by Technology

8.1. Introduction
8.2. Biosensors
- 8.2.1. Electrochemical
- 8.2.2. Optical
8.3. Immunoassay
- 8.3.1. Chemiluminescence
- 8.3.2. Fluorescence
- 8.3.3. Lateral Flow
8.4. Molecular
- 8.4.1. Isothermal Amplification
- 8.4.2. Pcr

9. Point of Care Diagnostics Market, by Sample Type

9.1. Introduction
9.2. Blood
9.3. Saliva
9.4. Urine

10. Point of Care Diagnostics Market, by Mode Of Testing

10.1. Introduction
10.2. Instrument Based
10.3. Microfluidic Chips
10.4. Strip Based

11. Point of Care Diagnostics Market, by Application

11.1. Introduction
11.2. Cardiology
11.3. Coagulation
11.4. Diabetes Monitoring
11.5. Infectious Diseases
- 11.5.1. Bacterial
- 11.5.2. Parasitic
- 11.5.3. Viral
11.6. Pregnancy & Fertility

12. Point of Care Diagnostics Market, by End User

12.1. Introduction
12.2. Ambulatory Centers
12.3. Clinics
12.4. Home Healthcare
12.5. Hospitals

13. Point of Care Diagnostics Market, by Region

13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa

14. Point of Care Diagnostics Market, by Group

14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO

15. Point of Care Diagnostics Market, by Country

15.1. Introduction
15.2. United States
15.3. China
15.4. Germany
15.5. United Kingdom
15.6. India
15.7. Japan
15.8. Russia
15.9. Brazil
15.10. Canada
15.11. Italy
15.12. Mexico
15.13. France
15.14. Spain
15.15. Australia
15.16. South Korea

16. Competitive Landscape

16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
- 16.2.1. Concentration Ratio (CR)
- 16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025

17. Company Profiles

17.1. Abaxis, Inc.
17.2. Abbott Laboratories
17.3. Becton, Dickinson and Company
17.4. Bio-Rad Laboratories, Inc.
17.5. bioMerieux SA
17.6. Biosynex SA
17.7. Cardinal Health, Inc.
17.8. Chembio Diagnostic Systems, Inc.
17.9. Danaher Corporation
17.10. EKF Diagnostics Holdings plc
17.11. F. Hoffmann-La Roche Ltd
17.12. Helena Laboratories Corporation
17.13. Illumina, Inc.
17.14. Microlife Corporation
17.15. Nova Biomedical Corporation
17.16. QIAGEN N.V.
17.17. Quest Diagnostics Incorporated
17.18. QuidelOrtho Corporation
17.19. Radiometer Medical ApS
17.20. Sekisui Diagnostics LLC
17.21. Siemens Healthineers AG
17.22. Sysmex Corporation
17.23. Thermo Fisher Scientific Inc.
17.24. Trinity Biotech plc
17.25. Werfen, S.A.

18. Key Experts